{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=brca2+Gene+Mutation&page=2", "query": { "condition": "brca2 Gene Mutation", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=brca2+Gene+Mutation&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T07:30:23.973Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02163694", "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Veliparib Placebo", "type": "DRUG" }, { "name": "Veliparib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 513, "start_date": "2014-04-08", "completion_date": "2024-01-25", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 56, "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02163694" }, { "nct_id": "NCT00438906", "title": "Cancer of the Pancreas Screening Study (CAPS 3)", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Pancreatic Neoplasm", "Peutz-Jeghers Syndrome" ], "interventions": [ { "name": "Biopsy, Fine Needle Aspiration (FNA)", "type": "PROCEDURE" }, { "name": "Secretin (human synthetic) - ChiRhoClin", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 200, "start_date": "2006-12", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2021-06-18", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00438906" }, { "nct_id": "NCT02314156", "title": "Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BRCA1 Mutation Carrier", "BRCA2 Mutation Carrier", "Ductal Breast Carcinoma In Situ", "Lobular Breast Carcinoma In Situ", "Stage 0 Breast Cancer", "Stage IA Breast Cancer", "Stage IB Breast Cancer", "Stage IIA Breast Cancer", "Stage IIB Breast Cancer" ], "interventions": [ { "name": "Telapristone Acetate", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 67, "start_date": "2015-10", "completion_date": "2021-05", "has_results": true, "last_update_posted_date": "2023-02-22", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 3, "location_summary": "West Hollywood, California • Chicago, Illinois • New York, New York", "locations": [ { "city": "West Hollywood", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02314156" }, { "nct_id": "NCT00580112", "title": "An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 127, "start_date": "2007-06", "completion_date": "2011-08", "has_results": false, "last_update_posted_date": "2014-02-25", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 21, "location_summary": "Sedona, Arizona • Denver, Colorado • Torrington, Connecticut + 18 more", "locations": [ { "city": "Sedona", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Torrington", "state": "Connecticut" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Westminster", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00580112" }, { "nct_id": "NCT01945775", "title": "A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms", "BRCA 1 Gene Mutation", "BRCA 2 Gene Mutation" ], "interventions": [ { "name": "talazoparib", "type": "DRUG" }, { "name": "Physician's-Choice", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 431, "start_date": "2013-10-14", "completion_date": "2021-03-05", "has_results": true, "last_update_posted_date": "2022-01-20", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 207, "location_summary": "Flagstaff, Arizona • Scottsdale, Arizona • Antioch, California + 136 more", "locations": [ { "city": "Flagstaff", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Antioch", "state": "California" }, { "city": "Antioch", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01945775" }, { "nct_id": "NCT06972719", "title": "Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "BRCA1 Mutation", "BRCA2 Mutation" ], "interventions": [ { "name": "Experimental Arm", "type": "BEHAVIORAL" }, { "name": "SOC Arm", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "19 Years to 50 Years · Female only" }, "enrollment_count": 50, "start_date": "2025-09-30", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Durham, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06972719" }, { "nct_id": "NCT03470402", "title": "Decision Support for BRCA Testing in Ethnically Diverse Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Cancer", "BRCA1 Mutation", "BRCA2 Mutation", "Ovarian Cancer" ], "interventions": [ { "name": "RealRisks", "type": "OTHER" }, { "name": "BNAV", "type": "OTHER" }, { "name": "iNYP", "type": "OTHER" }, { "name": "Standard Educational Material", "type": "OTHER" }, { "name": "High-Risk Message", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "21 Years to 75 Years · Female only" }, "enrollment_count": 276, "start_date": "2017-12-13", "completion_date": "2020-08-17", "has_results": false, "last_update_posted_date": "2021-04-19", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03470402" }, { "nct_id": "NCT01591746", "title": "Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Pain, Postoperative", "BRCA1 Mutation", "BRCA2 Mutation", "Breast Diseases", "Neoplasms" ], "interventions": [ { "name": "Botulinum Toxin Type A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 131, "start_date": "2012-08", "completion_date": "2017-07-18", "has_results": true, "last_update_posted_date": "2019-10-10", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01591746" }, { "nct_id": "NCT03344965", "title": "Olaparib In Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer", "Invasive Breast Cancer", "Somatic Mutation Breast Cancer (BRCA1)", "Somatic Mutation Breast Cancer (BRCA2)", "CHEK2 Gene Mutation", "ATM Gene Mutation", "PALB2 Gene Mutation", "RAD51 Gene Mutation", "BRIP1 Gene Mutation", "NBN Gene Mutation" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beth Israel Deaconess Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2018-04-01", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-01-05", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 20, "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03344965" }, { "nct_id": "NCT03685331", "title": "HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer", "Locally Advanced Breast Cancer", "Advanced Breast Cancer", "BRCA2 Mutation", "BRCA1 Mutation" ], "interventions": [ { "name": "Palbociclib", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 9, "start_date": "2020-10-15", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-07-23T07:30:23.973Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03685331" } ] }